Skip to content
Industry experts discuss the differences between classic psychedelics and ketamine, the serotonin vs glutamate model, and the pharmacology of neuroplasticity.

Details

  • Second Stage
Date:
11/05/2022
Start Time:
9:50 am
End Time:
10:35

Dr. Michelle Weiner, DO, MPH

Integrative Pain Management Physician, Spine and Wellness Centers of America

Dr. Michelle Weiner is double board-certified in Interventional Pain Medicine and Physical Medicine and Rehabilitation and a partner in private practice at Spine and Wellness Centers of America. She i…

Dr. Reid Robison, MD MBA

Chief Clinical Officer, Numinus

Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry a…

Dr. Bruno Rasmussen, MD

CMO, BienStar Wellness

Dr. Bruno Rasmussen, CMO of Bienstar, has treated more than 2.000 patients with ibogaine in Brazil in the last 27 years. A former chief of the Emergency Room of the Medical Clinic of São Paulo Hospita…

Dr. Manesh Girn, PhD(c)

Psychedelic Neuroscientist, UCSF | Chief Research Officer, EntheoTech Bioscience

I’m a psychedelic neuroscientist currently working at UCSF with Dr. Robin Carhart-Harris on cutting-edge brain imaging research with psilocybin, and also have my feet in the psychedelic industry, as C…

Jeffrey Becker, MD

Chief Scientific Officer, Bexson Biomedical

Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in U.S. administering and documenting ketamine for depressi…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now